Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04587687 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
A Phase 2 study of Recurrent Follicular Lymphoma and Refractory Follicular Lymphoma, sponsored by Joseph Tuscano.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT04587687: Recruiting Phase 2 study of Recurrent Follicular Lymphoma and Refractory Follicular Lymphoma, sponsored by Joseph Tuscano.
NCT04587687 is a Phase 2 study of Recurrent Follicular Lymphoma and Refractory Follicular Lymphoma that is actively recruiting participants, run by Joseph Tuscano. The registered enrollment target is 23 participants, below the 32-participant average among 20 other Recurrent Follicular Lymphoma trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04587687, a Phase 2 study of Recurrent Follicular Lymphoma and Refractory Follicular Lymphoma, is actively recruiting participants, sponsored by Joseph Tuscano.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to determine if the combination of brentuximab vedotin plus bendamustine is safe and to determine the effectiveness of the combination.
Primary Outcome
Will be assessed per 2014 Lugano criteria and Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) criteria. Will be summarized with 95% confidence intervals.
Conditions Studied
Interventions
- DRUG Brentuximab Vedotin
- DRUG Bendamustine Hydrochloride
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-12-04 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT04587687 shows while recruiting
NCT04587687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 32-participant average among 20 other Recurrent Follicular Lymphoma trials with a reported enrollment target (28% lower).
The record links to 2 conditions, with Recurrent Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Brentuximab Vedotin is the first listed.
NCT04587687 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04587687 about?
NCT04587687 is a clinical study titled "Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma". This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called ved...
What is the current status of trial NCT04587687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2020-12-04. Estimated completion is 2026-12.
What conditions does trial NCT04587687 study?
This clinical trial studies the following conditions: Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma.
What interventions are being tested in trial NCT04587687?
The interventions under investigation include: Brentuximab Vedotin (DRUG), Bendamustine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04587687?
This trial is sponsored by Joseph Tuscano, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04587687 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04587687's enrollment target sits among peer trials
23 13th of 20 higher than 8 of 20 other Recurrent Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
RECRUITING · Phase 2
-
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 2
-
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Q702 for the Treatment of Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
- NCT04796012 · 23 participants · Phase 1
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI